Jung, Wolfram

[["dc.bibliographiccitation.firstpage","2476"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Leukemia & Lymphoma"],["dc.bibliographiccitation.lastpage","2480"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Hellige, Niels"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Binder, Mascha"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2020-12-10T18:43:56Z"],["dc.date.available","2020-12-10T18:43:56Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.3109/10428194.2016.1151510"],["dc.identifier.eissn","1029-2403"],["dc.identifier.issn","1042-8194"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78273"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","218"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Scandinavian Journal of Immunology"],["dc.bibliographiccitation.lastpage","229"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Hasenkamp, J."],["dc.contributor.author","Borgerding, A."],["dc.contributor.author","Uhrberg, M."],["dc.contributor.author","Falk, C."],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Wulf, G."],["dc.contributor.author","Jung, W."],["dc.contributor.author","Trümper, L."],["dc.contributor.author","Glass, B."],["dc.date.accessioned","2021-06-01T10:47:17Z"],["dc.date.available","2021-06-01T10:47:17Z"],["dc.date.issued","2008"],["dc.identifier.doi","10.1111/j.1365-3083.2007.02058.x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85548"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1365-3083"],["dc.relation.issn","0300-9475"],["dc.title","Self-tolerance of Human Natural Killer Cells Lacking Self-HLA-specific Inhibitory Receptors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","425"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","International Journal of Hematology"],["dc.bibliographiccitation.lastpage","428"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Szuszies, Christoph Johannes"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Koch, Raphael"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Wulf, Gerald G."],["dc.date.accessioned","2021-06-01T10:49:21Z"],["dc.date.available","2021-06-01T10:49:21Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1007/s12185-014-1678-8"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86254"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1865-3774"],["dc.relation.issn","0925-5710"],["dc.title","Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Boyadzhiev, Hristo"],["dc.contributor.author","Valk, Jakob"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Wulf, Gerald"],["dc.date.accessioned","2021-06-01T10:49:08Z"],["dc.date.available","2021-06-01T10:49:08Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00277-020-04237-6"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86181"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Stem cell transplantation for hemoglobinopathy Vila Real"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Immunology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Wurm-Kuczera, Rebecca Isabel"],["dc.contributor.author","Buentzel, Judith"],["dc.contributor.author","Koenig, Julia Felicitas Leni"],["dc.contributor.author","Legler, Tobias"],["dc.contributor.author","Valk, Jan-Jakob"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Rademacher, Jan-Gerd"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Wulf, Gerald Georg"],["dc.date.accessioned","2021-12-01T09:23:06Z"],["dc.date.available","2021-12-01T09:23:06Z"],["dc.date.issued","2021"],["dc.description.abstract","Purpose Extrinsic factors and genetic predisposition contribute to the etiology of sarcoidosis, converging in a phenotype of altered immune response associated with multisystemic inflammatory granulomatous tissue infiltration. Immunological reconstitution after hematopoietic stem cell transplantation (HSCT) may represent a unique window for the pathogenesis of the disease. We describe the incidence, clinicopathological features, and HLA associations of sarcoidosis after HSCT in a single-center cohort of patients, together with data from previously published cases. Methods We retrospectively analyzed clinical characteristics and HLA haplotypes from allogeneic (allo) or autologous (auto) HSCT patients from January 2001 through May 2021 at the University Medicine Goettingen (UMG), and data from previously published cases. Results A total number of 19 patients was identified. These included 4 patients from our center (3 allo HSCT and 1 auto HSCT) and 15 patients from the literature review. Thirteen patients had received an allo HSCT, and six patients had received an auto HSCT. Sarcoidosis occurred after a median interval of 20 (after allo HSCT) and 7 (after auto HSCT) months, respectively. The predominant HLA allele associated with sarcoidosis was HLA DRB1 03:01. Sarcoidosis involved the respiratory tract in 15 patients (three unknown, one without pulmonary involvement), and it was associated with graft-versus-host disease in 7 of 13 patients receiving allo HSCT. None of the donors or patients had a history of sarcoidosis before transplantation. Disease manifestations resolved with standard glucocorticoid treatment without long-term sequelae. Conclusion Sarcoidosis may occur at low frequency during reconstitution of the immune system after HSCT. HLA allele associations reflect the associations observed in the general population, particularly with DRB1 03:01. Further insights into the interplay between Tcell reconstitution and the development of sarcoidosis could also provide novel approaches to an improved understanding of the pathogenesis in sarcoidosis."],["dc.description.sponsorship","Open-Access-Finanzierung durch die Universitätsmedizin Göttingen 2021"],["dc.identifier.doi","10.3389/fimmu.2021.746996"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94562"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.eissn","1664-3224"],["dc.relation.orgunit","Klinik für Nephrologie und Rheumatologie"],["dc.rights","CC BY 4.0"],["dc.title","Sarcoidosis Following Hematopoietic Stem Cell Transplantation: Clinical Characteristics and HLA Associations"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Borgerding, Andrea"],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Missal, Inga"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Glass, Bertram"],["dc.date.accessioned","2018-11-07T08:57:59Z"],["dc.date.available","2018-11-07T08:57:59Z"],["dc.date.issued","2006"],["dc.format.extent","822A"],["dc.identifier.isi","000242440003693"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23535"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0006-4971"],["dc.title","Allo-reactive NK cells after HLA-matched allogeneic hematopoietic stem cell transplantation."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","877"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","884"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Wilhelm, Christian"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Glass, Bertram"],["dc.date.accessioned","2020-12-10T18:09:41Z"],["dc.date.available","2020-12-10T18:09:41Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1038/s41409-018-0360-9"],["dc.identifier.eissn","1476-5365"],["dc.identifier.issn","0268-3369"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73726"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","763"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Hematological Oncology"],["dc.bibliographiccitation.lastpage","776"],["dc.bibliographiccitation.volume","40"],["dc.contributor.affiliation","Shumilov, Evgenii; 1\r\nDepartment of Hematology and Medical Oncology\r\nUniversity Medicine Göttingen (UMG)\r\nGöttingen Germany"],["dc.contributor.affiliation","Hasenkamp, Justin; 1\r\nDepartment of Hematology and Medical Oncology\r\nUniversity Medicine Göttingen (UMG)\r\nGöttingen Germany"],["dc.contributor.affiliation","Maulhardt, Markus; 1\r\nDepartment of Hematology and Medical Oncology\r\nUniversity Medicine Göttingen (UMG)\r\nGöttingen Germany"],["dc.contributor.affiliation","Mazzeo, Paolo; 1\r\nDepartment of Hematology and Medical Oncology\r\nUniversity Medicine Göttingen (UMG)\r\nGöttingen Germany"],["dc.contributor.affiliation","Schmidt, Nicole; 1\r\nDepartment of Hematology and Medical Oncology\r\nUniversity Medicine Göttingen (UMG)\r\nGöttingen Germany"],["dc.contributor.affiliation","Boyadzhiev, Hristo; 1\r\nDepartment of Hematology and Medical Oncology\r\nUniversity Medicine Göttingen (UMG)\r\nGöttingen Germany"],["dc.contributor.affiliation","Jung, Wolfram; 1\r\nDepartment of Hematology and Medical Oncology\r\nUniversity Medicine Göttingen (UMG)\r\nGöttingen Germany"],["dc.contributor.affiliation","Ganster, Christina; 1\r\nDepartment of Hematology and Medical Oncology\r\nUniversity Medicine Göttingen (UMG)\r\nGöttingen Germany"],["dc.contributor.affiliation","Haase, Detlef; 1\r\nDepartment of Hematology and Medical Oncology\r\nUniversity Medicine Göttingen (UMG)\r\nGöttingen Germany"],["dc.contributor.affiliation","Wulf, Gerald; 1\r\nDepartment of Hematology and Medical Oncology\r\nUniversity Medicine Göttingen (UMG)\r\nGöttingen Germany"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Maulhardt, Markus"],["dc.contributor.author","Mazzeo, Paolo"],["dc.contributor.author","Schmidt, Nicole"],["dc.contributor.author","Boyadzhiev, Hristo"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Koch, Raphael"],["dc.contributor.author","Wulf, Gerald"],["dc.date.accessioned","2022-11-28T08:48:20Z"],["dc.date.available","2022-11-28T08:48:20Z"],["dc.date.issued","2022-04-18"],["dc.date.updated","2022-11-27T10:10:48Z"],["dc.description.abstract","Abstract\r\nSecond allogeneic stem cell transplantation (allo‐SCT2) represents a rescue option for selected patients (pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML). Still, relapse rates post‐allo‐SCT2 remain high and effective anti‐relapse strategies and predictive biomarkers remain to be defined. We here analyzed a cohort of 41 AML patients (pts) undergoing allo‐SCT2 in our center. Allo‐SCT2 induced a third hematologic complete remission (CR) in 37 pts, at costs of a 36% non‐relapse mortality rate. Furthermore, 19 pts eventually relapsed post allo‐SCT2. Addressing relapse after allo‐SCT2, 14 pts (74%) underwent cell‐based anti‐relapse strategies, including third allogeneic transplantation (allo‐SCT3; 3/14), donor lymphocyte infusions (DLIs) combined with either 5‐azacytidin and venetoclax (4/14) or chemotherapeutic agents (7/14). Notably, six of seven pts (86%) who received either allo‐SCT3 or a combination therapy of DLIs, 5‐azacytidine and venetoclax achieved CR despite poor cytogenetics post‐allo‐SCT2 (e.g., TP53). Finally, 11 of 41 pts were alive at the last follow‐up (seven CR2, three CR3, one partial remission) resulting in estimated 2‐ and 5‐year overall survival of 35% and 25%, respectively."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)"],["dc.description.sponsorship","Deutsche Krebshilfe"],["dc.identifier.doi","10.1002/hon.2995"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117282"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.eissn","1099-1069"],["dc.relation.issn","0278-0232"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.rights.uri","http://creativecommons.org/licenses/by-nc-nd/4.0/"],["dc.title","Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]